Literature DB >> 14656745

Toll-like receptors in normal and cystic fibrosis airway epithelial cells.

Amanda Muir1, Grace Soong, Sach Sokol, Bharat Reddy, Marisa I Gomez, Anna Van Heeckeren, Alice Prince.   

Abstract

Toll-like receptors (TLRs) mediate cellular responses to diverse microbial ligands. The distribution and function of TLRs in airway cells were studied to identify which are available to signal the presence of inhaled pathogens and to establish if differences in TLR expression are associated with the increased proinflammatory responses seen in cystic fibrosis (CF). Isogenic, polarized CF and control bronchial epithelial cell lines, human airway cells in primary culture, and cftr null and wild-type mice were compared. TLRs 1-10, MD2, and MyD88 were expressed in CF and normal cells. Only TLR2 transcription was modestly increased in CF as compared with normal epithelial cells following bacterial stimulation. TLR2 was predominantly at the apical surface of airway cells and was mobilized to cell surface in response to bacteria. TLR4 was present in a more basolateral distribution in airway cells, but appeared to have a limited role in epithelial responses. Lipopolysaccharide failed to activate nuclear factor-kappaB in these cells, and TLR2 dominant negative but not TLR4 dominant negative mutants inhibited activation by both Gram-negative and Gram-positive bacteria. Increased availability of TLR2 at the apical surfaces of CF epithelial cells is consistent with the increased proinflammatory responses seen in CF airways and suggests a selective participation of TLRs in the airway mucosa.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14656745     DOI: 10.1165/rcmb.2003-0329OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  102 in total

Review 1.  Fungal Pathogens in CF Airways: Leave or Treat?

Authors:  A Singh; A Ralhan; C Schwarz; D Hartl; A Hector
Journal:  Mycopathologia       Date:  2017-08-02       Impact factor: 2.574

Review 2.  The role of secretory antibodies in infection immunity.

Authors:  Richard A Strugnell; Odilia L C Wijburg
Journal:  Nat Rev Microbiol       Date:  2010-08-09       Impact factor: 60.633

Review 3.  Innate Immune Signaling Activated by MDR Bacteria in the Airway.

Authors:  Dane Parker; Danielle Ahn; Taylor Cohen; Alice Prince
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

Review 4.  Control of local immunity by airway epithelial cells.

Authors:  M Weitnauer; V Mijošek; A H Dalpke
Journal:  Mucosal Immunol       Date:  2015-12-02       Impact factor: 7.313

Review 5.  The role of the microbiome in exacerbations of chronic lung diseases.

Authors:  Robert P Dickson; Fernando J Martinez; Gary B Huffnagle
Journal:  Lancet       Date:  2014-08-23       Impact factor: 79.321

6.  The type III pseudomonal exotoxin U activates the c-Jun NH2-terminal kinase pathway and increases human epithelial interleukin-8 production.

Authors:  Alayne Cuzick; Fiona R Stirling; Susan L Lindsay; Thomas J Evans
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

7.  CD14 signaling reciprocally controls collagen deposition and turnover to regulate the development of lyme arthritis.

Authors:  Bikash Sahay; Anju Singh; Arumugam Gnanamani; Rebeca L Patsey; J Edwin Blalock; Timothy J Sellati
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

8.  Nonclassical pathway of Pseudomonas aeruginosa DNA-induced interleukin-8 secretion in cystic fibrosis airway epithelial cells.

Authors:  Mónica A Delgado; Jens F Poschet; Vojo Deretic
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

9.  Mucosal adjuvant properties of the Shigella invasin complex.

Authors:  Robert W Kaminski; K Ross Turbyfill; Edwin V Oaks
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

10.  RNA interference as a potential therapeutic treatment for inflammation associated lung injury.

Authors:  Joanne Lomas-Neira; Chun-Shiang Chung; Alfred Ayala
Journal:  Int J Clin Exp Med       Date:  2008-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.